Spectrum Pharmaceuticals Inc (NASDAQ:SPPI)

18.47
Delayed Data
As of Apr 20
 -0.39 / -2.07%
Today’s Change
5.47
Today|||52-Week Range
23.50
-2.53%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.9B

Company Description

Spectrum Pharmaceuticals, Inc. engages in the acquisition, development, and commercialization of pipeline of late-stage clinical and commercial products. It targets non-Hodgkin's lymphoma, advanced metastatic colorectal cancer, acute lymphoblastic leukemia, and multiple myeloma. It operates through the following brands: FUSILEV, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ, EVOMELA, EOQUIN, and RenaZorb. The company was founded in December 1987 and is headquartered in Henderson, NV.

Contact Information

Spectrum Pharmaceuticals, Inc.
11500 South Eastern Avenue
Henderson Nevada 89052
P:(702) 835-6300
Investor Relations:

Employees

Shareholders

Individual stakeholders7.58%
Mutual fund holders45.29%
Other institutional40.31%

Top Executives

Joseph W. TurgeonPresident, Chief Executive Officer & Director
Thomas J. RigaExecutive VP, Chief Operating & Commercial Officer
Kurt A. GustafsonChief Financial Officer & Executive Vice President
Guru ReddyVice President-Preclinical Research & Development
Keith M. McGahanChief Legal Officer & Senior Vice President